Let’s Connect

Advancing Safety in
Oligonucleotide Therapeutics

The Oligonucleotide Safety Working Group (OSWG) unites scientists, regulators, and industry to ensure safer, more effective therapies reach patients worldwide.

Our Story

Founded as a response to the growing need for clarity in oligonucleotide safety evaluation, OSWG began as a forum for discussion and has grown into a recognized global platform. Over the years, we have built a network that spans academia, industry, and regulatory bodies.
Our Journey reflects the shared belief that collaboration and harmonization are essential to overcoming challenges in this rapidly evolving field.

Our Mission

OSWG accelerates the safe development of oligonucleotide therapies by uniting diverse expertise to establish best practices that move treatments from research to patients with confidence.

Establishing clear, harmonized safety
evaluation standards.

Encouraging transparent data sharing
across stakeholders.

Supporting innovation while maintaining patient safety.

Objectives

To share information, facilitate dialog and enable discussion on issues (observed and anticipated) in the development of synthetic oligonucleotides as drugs.

Reflect current thinking of members, companies and regulatory authorities on issues.

Our Goals
Provide recommendations on the "best practice" for nonclinical development of oligonucleotides-based therapeutics
Passing on our legacy of oligo safety assessment expertise to the next generation of oligo scientists
DIA/FDA oligonucleotide meeting organization and participation
Generate white papers
Our Community

The strength of OSWG lies in its members. Our
community includes:

Scientists pushing the boundaries of
nonclinical and clinical research.
Industry professionals developing next-generation therapies.
Regulators ensuring safety frameworks meet real-world needs.
Academics and clinicians who bring diverse perspectives to critical safety questions.